Journal of Innate Immunity· 2016Q1
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
- 4,998citations
- Q1SCImago
- 2016year
Short summary
(R)-Roscovitine, a kinase inhibitor in trials for cancer and other diseases, shows potential for cystic fibrosis (CF) by partially protecting F508del-CFTR, restoring macrophage bactericidal activity, resolving inflammation, and offering analgesic properties.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Epidemiology
EpidemiologyMedicine